|
1
|
Hochberg AR, Ho AH, Thompson RAM, Buck MB, Lallas CD, Ibilibor C, Tomaszewski JJ, Ginzburg S, Correa A, Uzzo R, Smaldone MC, Danella JF, Guzzo TJ, Lee DJ, Belkoff L, Walker J, Raman JD, Clark RK, Reese A, Jacobs B, Jang T, Kowalczyk KJ, Smith M, Shah MS. Real-World Management of High-Risk Prostate Cancer Post-Radical Prostatectomy: Insights from a Regional Quality Collaborative. Cancers (Basel) 2025; 17:1600. [PMID: 40427099 PMCID: PMC12109697 DOI: 10.3390/cancers17101600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2025] [Revised: 04/21/2025] [Accepted: 04/22/2025] [Indexed: 05/29/2025] Open
Abstract
Prostate cancer (CaP) remains the most diagnosed malignancy in men, and the incidence of high-grade disease at diagnosis is increasing [...].
Collapse
Affiliation(s)
- Aaron R. Hochberg
- Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA; (A.R.H.); (A.H.H.); (R.A.M.T.); (M.B.B.); (C.D.L.)
| | - Annie H. Ho
- Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA; (A.R.H.); (A.H.H.); (R.A.M.T.); (M.B.B.); (C.D.L.)
| | - Rasheed A. M. Thompson
- Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA; (A.R.H.); (A.H.H.); (R.A.M.T.); (M.B.B.); (C.D.L.)
- Department of Urology, Howard University College of Medicine, Washington, DC 20059, USA
| | - Matthew B. Buck
- Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA; (A.R.H.); (A.H.H.); (R.A.M.T.); (M.B.B.); (C.D.L.)
| | - Costas D. Lallas
- Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA; (A.R.H.); (A.H.H.); (R.A.M.T.); (M.B.B.); (C.D.L.)
| | - Christine Ibilibor
- Department of Urology, University of Virginia, Charlottesville, VA 22904, USA;
| | | | - Serge Ginzburg
- Department of Urology, Einstein Healthcare Network, Philadelphia, PA 19141, USA;
| | - Andres Correa
- Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA; (A.C.); (R.U.); (M.C.S.)
| | - Robert Uzzo
- Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA; (A.C.); (R.U.); (M.C.S.)
| | - Marc C. Smaldone
- Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA; (A.C.); (R.U.); (M.C.S.)
| | - John F. Danella
- Department of Urology, Geisinger Health System, Danville, PA 17822, USA;
| | - Thomas J. Guzzo
- Division of Urology, University of Pennsylvania, Philadelphia, PA 19104, USA; (T.J.G.); (D.J.L.)
| | - Daniel J. Lee
- Division of Urology, University of Pennsylvania, Philadelphia, PA 19104, USA; (T.J.G.); (D.J.L.)
| | - Laurence Belkoff
- Division of Urology, MidLantic Urology, Main Line Health, Bala Cynwyd, PA 19010, USA; (L.B.); (J.W.)
| | - Jeffrey Walker
- Division of Urology, MidLantic Urology, Main Line Health, Bala Cynwyd, PA 19010, USA; (L.B.); (J.W.)
| | - Jay D. Raman
- Department of Urology, Penn State Health, Hershey, PA 17033, USA; (J.D.R.)
| | - Roderick K. Clark
- Department of Urology, Penn State Health, Hershey, PA 17033, USA; (J.D.R.)
| | - Adam Reese
- Department of Urology, Temple University, Philadelphia, PA 19122, USA;
| | - Bruce Jacobs
- Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA 15261, USA;
| | - Thomas Jang
- Division of Urology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA;
| | - Keith J. Kowalczyk
- Department of Urology, MedStar Health Georgetown, Washington, DC 20007, USA;
| | - Meghan Smith
- Health Care Improvement Foundation, Philadelphia, PA 19103, USA;
| | - Mihir S. Shah
- Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA; (A.R.H.); (A.H.H.); (R.A.M.T.); (M.B.B.); (C.D.L.)
| |
Collapse
|
|
2
|
Cottrell TR, Lotze MT, Ali A, Bifulco CB, Capitini CM, Chow LQM, Cillo AR, Collyar D, Cope L, Deutsch JS, Dubrovsky G, Gnjatic S, Goh D, Halabi S, Kohanbash G, Maecker HT, Maleki Vareki S, Mullin S, Seliger B, Taube J, Vos W, Yeong J, Anderson KG, Bruno TC, Chiuzan C, Diaz-Padilla I, Garrett-Mayer E, Glitza Oliva IC, Grandi P, Hill EG, Hobbs BP, Najjar YG, Pettit Nassi P, Simons VH, Subudhi SK, Sullivan RJ, Takimoto CH. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols. J Immunother Cancer 2025; 13:e010928. [PMID: 40054999 PMCID: PMC11891540 DOI: 10.1136/jitc-2024-010928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2024] [Accepted: 02/05/2025] [Indexed: 03/12/2025] Open
Abstract
Immunotherapy of cancer is now an essential pillar of treatment for patients with many individual tumor types. Novel immune targets and technical advances are driving a rapid exploration of new treatment strategies incorporating immune agents in cancer clinical practice. Immunotherapies perturb a complex system of interactions among genomically unstable tumor cells, diverse cells within the tumor microenvironment including the systemic adaptive and innate immune cells. The drive to develop increasingly effective immunotherapy regimens is tempered by the risk of immune-related adverse events. Evidence-based biomarkers that measure the potential for therapeutic response and/or toxicity are critical to guide optimal patient care and contextualize the results of immunotherapy clinical trials. Responding to the lack of guidance on biomarker testing in early-phase immunotherapy clinical trials, we propose a definition and listing of essential biomarkers recommended for inclusion in all such protocols. These recommendations are based on consensus provided by the Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Network (SCION) faculty with input from the SITC Pathology and Biomarker Committees and the Journal for ImmunoTherapy of Cancer readership. A consensus-based selection of essential biomarkers was conducted using a Delphi survey of SCION faculty. Regular updates to these recommendations are planned. The inaugural list of essential biomarkers includes complete blood count with differential to generate a neutrophil-to-lymphocyte ratio or systemic immune-inflammation index, serum lactate dehydrogenase and albumin, programmed death-ligand 1 immunohistochemistry, microsatellite stability assessment, and tumor mutational burden. Inclusion of these biomarkers across early-phase immunotherapy clinical trials will capture variation among trials, provide deeper insight into the novel and established therapies, and support improved patient selection and stratification for later-phase clinical trials.
Collapse
Affiliation(s)
- Tricia R Cottrell
- Queen's University Sinclair Cancer Research Institute, Kingston, Ontario, Canada
| | | | - Alaa Ali
- Stem Cell Transplant and Cellular Immunotherapy Program, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, Washington, DC, USA
| | - Carlo B Bifulco
- Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA
| | - Christian M Capitini
- University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, Wisconsin, USA
| | | | - Anthony R Cillo
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA
- Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Deborah Collyar
- Patient Advocates In Research (PAIR), Danville, California, USA
| | - Leslie Cope
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
| | | | | | - Sacha Gnjatic
- Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Denise Goh
- Institute of Molecular and Cell Biology (IMCB), Agency of Science, Technology and Research (A*STAR), Singapore
| | - Susan Halabi
- Duke School of Medicine and Duke Cancer Institute, Durham, North Carolina, USA
| | - Gary Kohanbash
- Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
- Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Holden T Maecker
- Stanford University School of Medicine, Stanford, California, USA
| | - Saman Maleki Vareki
- Department of Oncology and Pathology and Laboratory Medicine, Western University, London, Ontario, Canada
| | - Sarah Mullin
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
| | - Barbara Seliger
- Campus Brandenburg an der Havel, Brandenburg Medical School, Halle, Germany
| | - Janis Taube
- Johns Hopkins School of Medicine, Baltimore, Maryland, USA
| | - Wim Vos
- Radiomics.bio, Liège, Belgium
| | - Joe Yeong
- Institute of Molecular and Cell Biology (IMCB), Agency of Science, Technology and Research (A*STAR), Singapore
- Department of Anatomical Pathology, Singapore General Hospital, Singapore
| | - Kristin G Anderson
- Department of Microbiology, Immunology and Cancer Biology, Department of Obstetrics and Gynecology, Beirne B. Carter Center for Immunology Research and the University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, Virginia, USA
| | - Tullia C Bruno
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA
- Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
- Tumor Microenvironment Center, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
- Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA
| | - Codruta Chiuzan
- Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, USA
| | | | | | | | | | - Elizabeth G Hill
- Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Brian P Hobbs
- Dell Medical School, The University of Texas, Austin, Texas, USA
| | - Yana G Najjar
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA
| | | | | | - Sumit K Subudhi
- The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Ryan J Sullivan
- Massachusetts General Hospital, Harvard Medical School, Needham, Massachusetts, USA
| | | |
Collapse
|